Centessa, formed earlier this year through a ten-way merger involving multiple spinouts, has completed a listing in the US.

Centessa Pharmaceutical, a UK-based pharmaceutical conglomerate formed through a ten-way merger involving spinouts from various universities, went public in a $330m initial public offering on Friday.

The company issued 16.5 million American Depositary Shares, representing the same number of ordinary shares, priced at $20 each. The spinout now trades on the Nasdaq Global Select Market using the ticker symbol CNTA and its shares closed at $21.75 on the first day of trading.

Founded in October 2020 as a holding…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.